INTERPACE BIOSCIENCES, INC. (IDXG) financial statements (2022 and earlier)

Company profile

Business Address MORRIS CORPORATE CENTER 1,
PARSIPPANY, NJ 07054
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)
Annual | Quarterly

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,0642,7722,3216,06815,199602
Cash and cash equivalents3,0642,7722,3216,06815,199602
Restricted cash and investments250     
Receivables6,1588,02810,3389,4833,4372,209
Inventory, net of allowances, customer advances and progress billings1,7862,0521,825   
Inventory1,7862,0521,825   
Other current assets2,6942,7223,8512,1701,1721,415
Other undisclosed current assets(1,786)(1,452)(1,825)  14
Total current assets:12,16614,12216,51017,72119,8084,240
Noncurrent Assets
Operating lease, right-of-use asset4,0324,384 ✕✕✕
Property, plant and equipment6,3497,3496,814837654929
Intangible assets, net (including goodwill)15,72019,78424,28229,85333,10536,358
Goodwill8,4338,4338,433   
Intangible assets, net (excluding goodwill)7,28711,35115,84929,85333,10536,358
Disposal group, including discontinued operation, noncurrent assets     14
Other noncurrent assets16042423131251
Other undisclosed noncurrent assets  3,892  (14)
Total noncurrent assets:26,26131,55935,03030,72133,79037,538
TOTAL ASSETS:38,42745,68151,54048,44253,59841,778
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,91617,4677,6507,5746,78912,113
Accounts payable2,6944,5114,7091,0593912,326
Accrued liabilities9,1989,7951975,0915,0046,236
Employee-related liabilities3,0243,1612,3411,4241,3943,551
Taxes payable  403   
Deferred revenue  457✕✕✕
Debt  1,505   
Due to related parties  888   
Disposal group, including discontinued operation7667667669181,3024,128
Business combination, contingent consideration, liability  502   
Other undisclosed current liabilities  5,524   
Total current liabilities:15,68218,23317,2928,4928,09116,241
Noncurrent Liabilities
Long-term debt and lease obligation, including:3,2133,6782,714  7,908
Long-term debt, excluding current maturities7,942    7,908
Finance lease, liability 138123✕✕✕
Operating lease, liability3,1543,5402,591✕✕✕
Other undisclosed long-term debt and lease obligation(7,883)     
Liabilities, other than long-term debt, including:6,0316,4554,5733,9584,2893,844
Liability for uncertainty in income taxes   3,8383,7343,594
Regulatory liability     250
Other liabilities4,6484,6374,57312082 
Business combination, contingent consideration, liability1,3831,818    
Other undisclosed liabilities, other than long-term debt    473 
Other undisclosed noncurrent liabilities9,383(138)5,2683611,3497,254
Total noncurrent liabilities:18,6279,99512,5554,3195,63819,006
Other undisclosed liabilities   2,693  
Total liabilities:34,30928,22829,84715,50413,72935,247
Temporary equity, carrying amount46,536 26,172   
Stockholders' equity
Stockholders' equity attributable to parent(42,418)(29,083)(4,479)32,93839,8696,531
Common stock40340239328727822
Treasury stock, value(1,868)(1,773)(1,721)(1,680)(1,671)(1,643)
Additional paid in capital186,106184,404182,514175,820173,062127,736
Accumulated deficit(227,059)(212,116)(185,665)(141,489)(131,800)(119,584)
Other undisclosed stockholders' equity 46,536    
Total stockholders' equity:(42,418)17,453(4,479)32,93839,8696,531
TOTAL LIABILITIES AND EQUITY:38,42745,68151,54048,44253,59841,778

Income statement (P&L) ($ in thousands)
Annual | Quarterly

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues41,31432,39824,22021,89615,89713,085
Revenue, net✕✕✕✕15,89713,085
Cost of revenue(23,369)(21,673)(15,888)(10,197)(7,358)(6,641)
Cost of goods and services sold   (10,197)  
Gross profit:17,94510,7258,33211,6998,5396,444
Operating expenses(31,942)(36,791)(34,768)(23,818)(14,832)(12,886)
Operating loss:(13,997)(26,066)(26,436)(12,119)(6,293)(6,442)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))		(496)467196263(2,128)14
Interest and debt expense(920)(549)(440)(331)(4,711)(2,144)
Loss from continuing operations before income taxes:(15,413)(26,148)(26,680)(12,187)(13,132)(8,572)
Income tax expense (benefit)667(53)28(18)395162
Loss from continuing operations:(14,746)(26,201)(26,652)(12,205)(12,737)(8,410)
Income (loss) from discontinued operations(197)(250)(88)1652178
Net loss attributable to parent:(14,943)(26,451)(26,740)(12,189)(12,216)(8,332)
Preferred stock dividends and other adjustments (3,033)(429)   
Net loss available to common stockholders, diluted:(14,943)(29,484)(27,169)(12,189)(12,216)(8,332)

Comprehensive Income ($ in thousands)
Annual | Quarterly

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(14,943)(26,451)(26,740)(12,189)(12,216)(8,332)
Comprehensive loss, net of tax, attributable to parent:(14,943)(26,451)(26,740)(12,189)(12,216)(8,332)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: